Claims for Patent: 6,867,293

Summary for Patent: 6,867,293

Title:	Polynucleotide constructs having at least one transcriptional enhancer and encoding a modified rice EPSPS enzyme
Abstract:	The invention is directed to polynucleotide constructs having at least one transcriptional enhancer operably liked to a rice EPSPS promoter and to a sequence encoding the rice EPSPS chloroplast transit peptide and rice EPSPS enzyme, the encoded enzyme having a modified region that confers herbicide resistance.
Inventor(s):	Andrews; Christopher John (Bracknell, GB), Bachoo; Satvinder (Bracknell, GB), Hawkes; Timothy Robert (Bracknell, GB), Pickerill; Andrew Paul (Bracknell, GB), Warner; Simon Anthony James (Bracknell, GB)
Assignee:	Syngenta Limited (Guilford, GB)
Application Number:	10/012,070
Patent Claims:	1. An isolated polynucleotide comprising the following components in the 5' to 3' direction of transcription: (i) at least one transcriptional enhancer sequence, selected from the group consisting of SEQ ID NOS 45, 46, 47, 48, 49, 50, and 51; (ii) a sequence selected from the group consisting of SEQ ID NOS 52, 53, and 54, which comprises the promoter from the rice EPSPS gene; (iii) the rice genomic sequence which encodes the rice EPSPS chloroplast transit peptide and encodes the rice EPSPS enzyme of SEQ ID NO 43; and (iv) a transcriptional terminator sequence; wherein the rice EPSPS coding sequence is modified in that a first position is mutated so that the residue at this position is Ile rather than Thr and a second position is mutated so that the residue at this position is Ser rather than Pro, the mutations being introduced into EPSPS sequences which comprise the following conserved region GNAGTAMRPLTAAV (SEQ ID NO 56) in the wild type enzyme (SEQ ID NO 43) such that modified sequence (SEQ ID NO 44) reads GNAGIAMRSLTAAV (SEQ ID NO 57). 2. The polynucleotide according to claim 1, which comprises two transcriptional enhancers selected from the group consisting of the enhancers depicted in SEQ ID Nos 45, 46, 47, 48, 49, 50, and 51. 3. The polynucleotide according to claim 2, in which the transcriptional enhancers are tandemly present in the polynucleotide. 4. The polynucleotide according to claim 1, wherein the 3' end of the enhancer is between about 100 to about 1000 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 5. The polynucleotide according to claim 2, wherein the 3' end of the first enhancer is between about 100 to about 1000 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 6. The polynucleotide according to claim 1, further comprising an intron, and wherein the 3' end of the enhancer is between about 100 to about 1000 nucleotides upstream of the first nucleotide of the intron in the untranslated region. 7. The polynucleotide of claim 6 wherein the intron has the sequence depicted in SEQ ID NO 55. 8. The polynucleotide according to claim 1, wherein the 3' end of the enhancer is between about 300 to about 950 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 9. The polynucleotide according to claim 2, wherein the 3' end of the first enhancer is between about 300 to about 950 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 10. The polynucleotide according to claim 1, further comprising an intron, and wherein the 3' end of the enhancer is between about 300 to about 950 nucleotides upstream of the first nucleotide of the intron in the untranslated region. 11. The polynucleotide of claim 10 wherein the intron has the sequence depicted in SEQ ID NO 55. 12. The polynucleotide according to claim 1, wherein the 3' end of the enhancer is between about 770 to about 790 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 13. The polynucleotide according to claim 2, wherein the 3' end of the first enhancer is between about 770 to about 790 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 14. The polynucleotide according to claim 1, further comprising an intron, and wherein the 3' end of the enhancer is between about 770 to about 790 nucleotides upstream of the first nucleotide of the intron in the untranslated region. 15. The polynucleotide of claim 14 wherein the intron has the sequence depicted in SEQ ID NO 55. 16. The polynucleotide according to claim 1, wherein the 3' end of the enhancer is between about 300 to about 380 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 17. The polynucleotide according to claim 2, wherein the 3' end of the first enhancer is between about 300 to about 380 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 18. The polynucleotide according to claim 1, further comprising an intron, and wherein the 3' end of the enhancer is between about 300 to about 380 nucleotides upstream of the first nucleotide of the intron in the untranslated region. 19. The polynucleotide of claim 18 wherin the intron has the sequence depicted in SEQ ID NO 55. 20. The polynucleotide according to claim 1, wherein the 3' end of the enhancer is between about 320 to about 350 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 21. The polynucleotide according to claim 2, wherein the 3' end of the first enhancer is between about 320 to about 350 nucleotides upstream of the codon corresponding to the translational start of the EPSPS transit peptide. 22. The polynucleotide according to claim 1, further comprising an intron, and wherein the 3' end of the enhancer is between about 320 to about 350 nucleotides upstream of the first nucleotide of the intron in the untranslated region. 23. The polynucleotide of claim 22 wherein the intron has the sequence depicted in SEQ ID NO 55. 24. The polynucleotide according to claim 1, wherein the enhancer has the sequence depicted in SEQ ID NO. 45 or 46. 25. The polynucleotide according to claim 2, wherein in a 5' to 3' direction the first enhancer has the sequence depicted in SEQ ID NO 50 and the second enhancer has the sequence depicted in SEQ ID Nos 45 or 46. 26. The polynucleotide according to claim 2, wherein in a 5' to 3' direction the first enhancer has the sequence depicted in SEQ ID NO 49 and the second enhancer has the sequence depicted in SEQ ID Nos 45 or 46. 27. The polynucleotide according to claim 2, wherein in a 5' to 3' direction the first enhancer has the sequence depicted in SEQ ID NO 51 and the second enhancer has the sequence depicted in SEQ ID Nos 45 or 46. 28. The polynucleotide according to claim 2, wherein in a 5' to 3' direction the first enhancer has the sequence depicted in SEQ ID NO 48 and the second enhancer has the sequence depicted in SEQ ID Nos 45 or 46. 29. The polynucleotide according to claim 2, wherein in a 5' to 3' direction the first enhancer has the sequence depicted in SEQ ID NO 45 and the second enhancer has the sequence depicted in SEQ ID Nos 45 or 46. 30. The polynucleotide according to claim 1, which further comprises a sequence which encodes a protein which confers upon plant material transformed with the polynucleotide at least one of the following traits, resistance to insects, fungi, viruses, bacteria, nematodes, stress, desiccation or herbicides. 31. The polynucleotide according to claim 30, wherein the insect resistance protein is selected from the group consisting of cryIAc, cryIAb, cry3A, Vip 1A, Vip 1B, a cystein protease inhibitor and snow drop lectin; the fungus resistance protein is selected from the group consisting of a defensin, a chitinase, a glucanase and Avr-Cf9; the virus resistance protein is selected from the group consisting of a cecropin and a techyplesin, and the virus resistance protein is selected from the group consisting of a viral coat protein, a movement protein and a viral replicase.

Details for Patent 6,867,293

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-03-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-03-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-03-29